Protein and mRNA Expression Levels of Interleukin-17A, -17F and -22 in Blood and Skin Samples of Patients with Mycosis Fungoides.
CTCL
IL-17A
IL-17F
IL-22
primary cutaneous T-cell lymphoma
mycosis fungoides
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
18 Nov 2020
18 Nov 2020
Historique:
pubmed:
11
11
2020
medline:
24
6
2021
entrez:
10
11
2020
Statut:
epublish
Résumé
This study investigated the expression of interleukin (IL)-17A, -17F and -22 in mycosis fungoides. Blood samples were collected from 50 patients with mycosis fungoides and 50 healthy controls. Skin samples were obtained from 26 patients with mycosis fungoides and 5 healthy controls. Protein levels of IL-17A, -17F and -22 were measured in serum by multiplex enzyme-linked immunosorbent assay, and mRNA expression levels were measured in blood and skin samples by real-time quantitative reverse transcription PCR. Both IL-17A and IL-17F mRNA expression levels were significantly lower in blood of patients with mycosis fungoides in comparison with healthy controls. IL-22 serum levels and expression levels of IL-22 mRNA in skin tissue, were significantly increased in patients with mycosis fungoides in comparison with healthy controls. These results suggest that low levels of IL-17A and IL-17F in mycosis fungoides may be connected to impaired immune surveillance contributing to tumourigenesis. Upregulation of IL-22 may play a role in the establishment of the tumour microenvironment in mycosis fungoides.
Identifiants
pubmed: 33170303
doi: 10.2340/00015555-3688
pmc: PMC9309846
doi:
Substances chimiques
IL17A protein, human
0
IL17F protein, human
0
Interleukin-17
0
Interleukins
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv00326Références
J Eur Acad Dermatol Venereol. 2016 Oct;30(10):e31-e32
pubmed: 26337297
Blood Adv. 2019 Feb 26;3(4):519-530
pubmed: 30770361
Clin Cancer Res. 2014 Nov 1;20(21):5507-16
pubmed: 25212608
J Invest Dermatol. 2012 Jul;132(7):1933-5
pubmed: 22297633
J Invest Dermatol. 2014 Apr;134(4):984-991
pubmed: 24352038
Cytokine Growth Factor Rev. 2014 Jun;25(3):257-71
pubmed: 24856143
Eur J Dermatol. 2018 Apr 1;28(2):235-236
pubmed: 29336316
N Engl J Med. 2005 May 5;352(18):1899-912
pubmed: 15872205
Eur J Immunol. 2018 Jan;48(1):15-31
pubmed: 29178520
Cancer Biol Ther. 2011 Dec 15;12(12):1019-22
pubmed: 22236880
Nat Rev Immunol. 2010 Apr;10(4):248-56
pubmed: 20336152
Annu Rev Pathol. 2013 Jan 24;8:477-512
pubmed: 23157335
Br J Dermatol. 2014 Mar;170(3):609-16
pubmed: 24125475
Int J Cancer. 2004 Oct 20;112(1):113-20
pubmed: 15305382
Br J Dermatol. 2013 Apr;168(4):881-3
pubmed: 23013419
Clin Cancer Res. 2008 Feb 1;14(3):646-53
pubmed: 18245523
J Invest Dermatol. 2014 Sep;134(9):2351-2360
pubmed: 24658504
J Dermatol Sci. 2013 Oct;72(1):3-8
pubmed: 23746568
J Invest Dermatol. 2015 Mar;135(3):673-678
pubmed: 25339380
Nat Immunol. 2009 Aug;10(8):857-63
pubmed: 19578369
Clin Exp Dermatol. 2019 Jun;44(4):414-417
pubmed: 30284290
Annu Rev Immunol. 2007;25:821-52
pubmed: 17201677
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Nat Immunol. 2009 Aug;10(8):864-71
pubmed: 19578368
Biomed Res Int. 2015;2015:327470
pubmed: 26583100
Br J Dermatol. 2019 Aug;181(2):350-357
pubmed: 30267549
Cell Cycle. 2014;13(8):1306-12
pubmed: 24621498
Nat Rev Immunol. 2018 Nov;18(11):671-688
pubmed: 30209347
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Br J Haematol. 2011 Oct;155(2):150-66
pubmed: 21883142
Clin Exp Allergy. 2014 Aug;44(8):1033-43
pubmed: 24912880
Clin Cancer Res. 2011 Dec 15;17(24):7529-38
pubmed: 22048239
Blood. 2013 Aug 8;122(6):943-50
pubmed: 23801634
J Invest Dermatol. 2011 Jun;131(6):1331-8
pubmed: 21346774